Neoadjuvant and Frontline Studies Guide Malignant Melanoma Treatment

Christina T. Loguidice
Published: Thursday, Sep 19, 2019
Ryan J. Sullivan, MD

Ryan J. Sullivan, MD

The development of targeted therapies and immune checkpoint inhibitors has changed the management of malignant melanoma, providing safer and more effective treatment options and improving outcomes for many patients with this malignancy. However, the question of how best to use these and other treatments, such as oncolytic viruses, to optimize outcomes remains unanswered.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Community Practice Connections™: 15th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20202.0
Publication Bottom Border
Border Publication
x